A pilot study on ex vivo expanded autologous adipose‐derived stem cells of improving fat retention in localized scleroderma patients

• Main Authors: Chenyu Wang, Xiao Long, Loubin Si, Bo Chen, Yiwei Zhang, Tianyu Sun, Xiuqin Zhang, Robert Chunhua Zhao, Xiaojun Wang
• Format: Article
• Language: English
• Published: Wiley 2021-08-01
• Series: Stem Cells Translational Medicine
• Subjects: adipose‐derived stem cells; fat grafting; localized scleroderma; stromal vascular fraction
• Online Access: https://doi.org/10.1002/sctm.20-0419

Abstract In patients with localized scleroderma (LoS), facial deformity induced by subcutaneous atrophy greatly reduces life quality. Autologous fat grafting (AFG) is used for volume restoration but with low‐fat retention due to various reasons. Adipose‐derived stem cells (ADSCs) have shown potential effects in improving fat retention. We aimed to compare the feasibility and efficacy of improving fat retention in LoS patients among the ADSCs‐assisted, the stromal vascular fraction (SVF)‐assisted and conventional AFG methods. A pilot study with a 6‐month follow‐up among 18 LoS patients was conducted. Participants were randomly assigned into three AFG groups: conventional group, SVF‐assisted group, and ADSCs‐assisted group. The SVF‐assisted group received SVF‐assisted AFG at the SVF:fat ratio of 1:1. The ADSCs‐assisted group received the mixture of ADSCs‐enriched fat graft supplemented with 5 × 105 ADSCs/mL fat. Volume retention was measured by magnetic resonance imaging, and clinical photographs were taken for outcome evaluation. At sixth‐month follow‐up, the fat retention of ADSCs‐assisted group was 49.83 ± 3.61%, significantly higher than 31.75 ± 1.73% of SVF‐assisted group (P = .0004), and 21.86 ± 1.68% of the conventional group (P < .0001). A significant difference of the fat retention was also observed between the SVF‐assisted and conventional group (P = .0346). No severe adverse events occurred during the procedure and follow‐up. This pilot study suggests that ADSCs‐assisted AFG is a safe, feasible, and attractive alternative to conventional and SVF‐assisted AFG in the correction of facial atrophy of LoS patients. Future studies with large patient samples are needed for confirmation. (Chinese Clinical Trial Registry, ChiCTR1900025717).